Peter Attia· MD
these patients with Lynch are gonna be much more likely to be susceptible to checkpoint inhibitors
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
these patients with Lynch are gonna be much more likely to be susceptible to checkpoint inhibitors
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
but i think the checkpoint inhibitors also have this huge impact beyond just melanoma because anybody who shows up with a checkpoint mutation even if you have lynch syndrome and you go on to get pancreatic adenocarcinoma you're probably going to respond